Our Event Partners:

chinook_logo_colour

Chinook Therapeutics | Industry Partner

Chinook Therapeutics, Inc. was a clinical stage biopharmaceutical company which was acquired by Novartis on August 11, 2023. Chinook is now a Novartis Company developing precision medicines for kidney Diseases.  Chinook’s product candidates, including atrasentan, BION‐1301 and CHK‐336, and research & discovery programs, are being investigated in rare, severe chronic kidney disorders with opportunities for well‐defined clinical pathways.

 

To learn more, visit www.chinooktx.com.

 

medibeacon logo

MediBeacon | Exhibition Partner

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 275 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. Data readout of the TGFR Phase 3 Global Pivotal Study is expected in 2022.

www.medibeacon.com

Natera_Logo_Transparent Background

Natera | Event Partner

Natera provides advanced DNA technology that enables transplant providers to deliver quality, personalized care. As a diagnostics company with proprietary bioinformatics and molecular technology, we’ve performed more than 3 million cfDNA tests.

www.natera.com

2023_gubra_logo-blue

Gubra | Event Partner

Gubra provides a wide range of services within chronic kidney diseases enabling fast, data-driven decisions moving preclinical targets and drug discovery projects forward.

Our services include preclinical studies in a wide selection of rodent models of chronic kidney diseases, including polycystic kidney disease. Studies can be combined with high-end capabilities within histology, advanced single cell RNA sequencing, spatial transcriptomics and whole-organ 3D imaging.

www.gubra.dk